Febentel 1000 mg

For its established antiparasitic use, fenbendazole interferes with processes that susceptible worms need for survival. Its broad-spectrum activity covers several common types of intestinal worms when used according to the supplied product instructions.

Cancer researchers have examined fenbendazole for its effects on:

• Cancer-cell division

• Microtubule formation

• Glucose uptake

• Cellular energy production

• Abnormal cell growth

• Cancer-cell survival

These findings support further drug-repurposing research but do not confirm that Febentel 1000 mg treats or cures cancer in people. In COVID-19 research, fenbendazole was included in computational screening involving viral spike proteins. Computer modelling identifies compounds for further study but cannot demonstrate safety or effectiveness in the human body.

Fenbendazole binds to tubulin, a protein used to form microtubules. Susceptible worms depend on these structures to absorb glucose, produce energy and maintain normal cellular functions. When microtubule formation is disrupted, the worms lose their energy supply and gradually die.

Cancer laboratory research has examined similar activity in rapidly dividing cancer cells. Experimental studies found that fenbendazole disrupted microtubule function, reduced glucose uptake and affected p53 and other pathways involved in controlling damaged cells.

COVID-19 research has focused on predicted interactions between fenbendazole and viral proteins through computer modelling. These predicted interactions require laboratory confirmation and controlled human testing before they can have clinical meaning.

The 1000 mg strength states the amount of fenbendazole contained in each tablet. It should not be treated as an established human dose for cancer, COVID-19 or parasitic infections.

There is no clinically established human cancer or COVID-19 dosage for Febentel 1000 mg. Online schedules involving daily tablets, treatment cycles or combinations with supplements have not been validated through controlled human trials.

Do not assume that a higher-strength tablet provides greater research or treatment benefits. Febentel 1000 mg should not be taken, divided or combined with other fenbendazole products based on online testimonials.

Anyone already using fenbendazole should tell their healthcare or oncology team the exact product strength, amount and frequency. Prescribed treatment should not be stopped, delayed or changed.

Common Side Effects: Reliable information about common side effects in people is unavailable because fenbendazole has not completed adequate human safety studies for these uses. Digestive discomfort, nausea, diarrhoea, reduced appetite, rash and allergic symptoms have been reported, but their frequency in people is not known.

Serious Side Effects: Published case reports have associated self-administered fenbendazole with severe drug-induced liver injury. Warning signs include yellow skin or eyes, dark urine, persistent nausea, loss of appetite, unusual tiredness and pain in the upper-right abdomen. Severe rash, facial swelling or breathing difficulty also requires urgent medical attention.

Febentel 1000 mg should not be used for cancer or COVID-19 self-treatment. Particular concern applies to:

• People with liver disease

• People with abnormal liver tests

• People receiving chemotherapy

• People receiving immunotherapy

• People taking antiviral medicines

• Pregnant or breastfeeding women

• Children and adolescents

• People allergic to benzimidazoles

• People enrolled in clinical trials

Human interaction studies involving fenbendazole are limited. Tell the healthcare or oncology team about every medicine and supplement being used.

Important combinations requiring medical review include:

• Chemotherapy medicines

• Immunotherapy medicines

• Targeted cancer treatments

• Hormonal cancer treatments

• Antiviral medicines

• Liver-affecting medicines

• Other benzimidazole medicines

• Herbal remedies and supplements

Combining fenbendazole with cancer treatment without informing the oncology team can make liver-test changes and treatment reactions more difficult to investigate.

• Keep the tablets in their original packaging.

• Follow the temperature printed on the product label.

• Protect the tablets from excessive heat and moisture.

• Keep the pack away from direct sunlight.

• Store it securely away from children and pets.

• Do not use tablets from damaged packaging.

• Check the batch number and expiry date.

• Dispose of expired tablets according to local requirements.